Drug Profile
Research programme: epoxyeicosanoids analogues - OMEICOS Therapeutics
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Max Delbruck Center for Molecular Medicine; University of Texas Southwestern Medical Center
- Developer OMEICOS Therapeutics
- Class Cardiovascular therapies; Epoxy compounds; Eye disorder therapies; Small molecules; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute kidney injury; Eye disorders; Myocardial infarction; Ventricular arrhythmias
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Eye-disorders in USA (PO)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Myocardial-infarction in Germany (PO)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Ventricular-arrhythmias in Germany (PO)